NeoImmuneTech’s Efineptakin Alfa (NT-I7) Receives the EMA’s Orphan Drug Designation to Treat Acute Radiation Syndrome
Shots:
- The EMA has granted orphan drug designation to the company’s efineptakin alfa (NT-I7) for the treatment of patients with Acute Radiation Syndrome (ARS)
- The company is developing efineptakin alfa for ARS under collaborations with the National Institute of Allergy and Infectious Diseases (NIAID) and Duke University, which received a $6M grant from NIAID for the same
- Additionally, the drug has also been designated with the US FDA’s ODD for the same indication in Nov 2023 and the EMA’s ODD for Idiopathic CD4+ Lymphocytopenia (ICL) in May 2017
Ref: NeoImmuneTech | Image: NeoImmuneTech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
